Comparative Pharmacology
Head-to-head clinical analysis: NORLESTRIN 21 1 50 versus VIORELE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORLESTRIN 21 1 50 versus VIORELE.
NORLESTRIN 21 1/50 vs VIORELE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing norethindrone (progestin) and ethinyl estradiol (estrogen). Inhibits ovulation via suppression of gonadotropins (LH, FSH). Enhances cervical mucus viscosity, reducing sperm penetration. Thins endometrium, decreasing implantation likelihood.
VIORELE is a monoclonal antibody that binds to and inhibits the activity of interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in the pathogenesis of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
One tablet (1 mg norethindrone acetate/50 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 days off therapy.
50 mg orally once daily
None Documented
None Documented
Norethindrone terminal half-life: 5-14 hours; ethinyl estradiol terminal half-life: 10-20 hours. Clinical context: steady-state reached within 5-7 days, clinically significant for missed dose management.
Terminal elimination half-life of 12–15 hours (mean 13.5 h) in healthy adults; may be prolonged in renal impairment (up to 30 h).
Norethindrone: renal (33% as metabolites), fecal (50%); ethinyl estradiol: renal (40% as glucuronide conjugates), fecal (60%)
Primarily renal (unchanged drug and metabolites, ~60%) and fecal (~30%), with minor biliary contribution (~10%).
Category C
Category C
Oral Contraceptive
Oral Contraceptive